BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Han A, Czajkowski L, Rosas LA, Cervantes-Medina A, Xiao Y, Gouzoulis M, Lumbard K, Hunsberger S, Reed S, Athota R, Baus HA, Lwin A, Sadoff J, Taubenberger JK, Memoli MJ. Safety and Efficacy of CR6261 in an Influenza A H1N1 Healthy Human Challenge Model. Clin Infect Dis 2020:ciaa1725. [PMID: 33211860 DOI: 10.1093/cid/ciaa1725] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Phillips AM, Maurer DP, Brooks C, Dupic T, Schmidt AG, Desai MM. Hierarchical sequence-affinity landscapes shape the evolution of breadth in an anti-influenza receptor binding site antibody.. [DOI: 10.1101/2022.09.21.508900] [Reference Citation Analysis]
2 Mcsweeney MD, Stewart I, Richardson Z, Kang H, Park Y, Kim C, Tiruthani K, Wolf W, Schaefer A, Kumar P, Aurora H, Hutchins J, Cho JM, Hickey AJ, Lee SY, Lai SK. Stable nebulization and muco‐trapping properties of regdanvimab/ IN ‐006 support its development as a potent, dose‐saving inhaled therapy for COVID ‐19. Bioengineering & Transla Med. [DOI: 10.1002/btm2.10391] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Moench TR, Botta L, Farrer B, Lickliter JD, Kang H, Park Y, Kim C, Hoke M, Brennan M, Mcsweeney MD, Richardson Z, Whelan JB, Cho JM, Lee SY, Faurot F, Hutchins J, Lai SK. A randomized, double-blind, Phase 1 study of IN-006, an inhaled antibody treatment for COVID-19.. [DOI: 10.1101/2022.08.17.22278748] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Park J, Fong Legaspi SL, Schwartzman LM, Gygli SM, Sheng Z, Freeman AD, Matthews LM, Xiao Y, Ramuta MD, Batchenkova NA, Qi L, Rosas LA, Williams SL, Scherler K, Gouzoulis M, Bellayr I, Morens DM, Walters K, Memoli MJ, Kash JC, Taubenberger JK. An inactivated multivalent influenza A virus vaccine is broadly protective in mice and ferrets. Sci Transl Med 2022;14:eabo2167. [DOI: 10.1126/scitranslmed.abo2167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Mcsweeney M, Stewart I, Richardson Z, Kang H, Park Y, Kim C, Tiruthani K, Wolf W, Schaefer A, Kumar P, Aurora H, Hutchins J, Cho JM, Hickey AJ, Lee SY, Lai S. Stable nebulization and muco-trapping properties of Regdanvimab/IN-006 supports its development as a potent, dose-saving inhaled therapy for COVID-19.. [DOI: 10.1101/2022.02.27.482162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Bitterman R, Kumar D. Respiratory Viruses in Solid Organ Transplant Recipients. Viruses 2021;13:2146. [PMID: 34834953 DOI: 10.3390/v13112146] [Reference Citation Analysis]
7 Giurgea LT, Cervantes-Medina A, Walters KA, Scherler K, Han A, Czajkowski LM, Baus HA, Hunsberger S, Klein SL, Kash JC, Taubenberger JK, Memoli MJ. Sex Differences in Influenza: The Challenge Study Experience. J Infect Dis 2021:jiab422. [PMID: 34423369 DOI: 10.1093/infdis/jiab422] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Bullard BL, Weaver EA. Strategies Targeting Hemagglutinin as a Universal Influenza Vaccine. Vaccines (Basel) 2021;9:257. [PMID: 33805749 DOI: 10.3390/vaccines9030257] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 17.0] [Reference Citation Analysis]